Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2014

Jan 24, 2014

32418_dirs_2014-01-23_77a19d39-fbb6-4525-94e2-6658daaa7056.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2014-01-21

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-01-21 Common Stock A 250000 Acquired 589165 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1429000 Indirect
Common Stock 6225155 Indirect

Footnotes

F1: The restricted shares are awarded to compensate for the efforts on behalf of the Corporation. These shares have certain vesting conditions and shall not vest on or before July 1, 2014.